CN Stock MarketDetailed Quotes

002252 Shanghai RAAS Blood Products

Watchlist
  • 7.96
  • +0.14+1.79%
Not Open Jul 1 15:00 CST
52.90BMarket Cap29.05P/E (TTM)

About Shanghai RAAS Blood Products Company

The company was founded in 1988 and listed on the Shenzhen Stock Exchange in June 2008. It is a leading domestic blood products enterprise integrating raw plasma collection, research and development, production and sales of blood products. The company's main business is the production and sale of blood products. The company's main products are human blood albumin, intravenous human immunoglobulin, specific immunoglobulins, coagulation factor products, etc. Shanghai Laishi is a “Shanghai Foreign-Invested Advanced Technology Enterprise” and a “High-tech Enterprise” certified by the Shanghai Science and Technology Commission. It has successively won the Forbes “2015 World's Most Innovative Companies List”, Forbes China's “Top 10 Most Innovative Companies in Asia 2015”, and “Top 20 Most Competitive Pharmaceutical Listed Companies”.

Company Profile

Short Name-A上海莱士
Symbol-A002252
Company NameShanghai RAAS Blood Products Co., Ltd.
Listing DateJun 23, 2008
Issue Price12.81
Shares Offered40.00M share(s)
FoundedOct 29, 1988
Listed ExchangeSZ Stock Exchange
Legal Representativejun xu
General Managerjun xu
Secretaryzheng liu
Accounting FirmKPMG Huazhen Certified Public Accountants (Special General Partnership)
Securities Representativehong qiu
Legal CounselBeijing Zhonglun (Shanghai) Law Firm
Employees632
Phone021-22130888-217
Office Address2009 Wangyuan Road, Fengxian District, Shanghai
Zip Code201401
Registered Address2009 Wangyuan Road, Fengxian District, Shanghai
Fax021-37515869
Emailraas@raas-corp.com
Business License310000400004034
BusinessProduces and sells blood products, vaccines, diagnostic reagents and testing instruments and testing technology, and provides testing services (licensing operations involving licensed operations).

Company Executives

  • Name
  • Position
  • Salary
  • jun xu
  • Chairman,directors,general manager
  • 5.15M
  • Tommy Trong Hoang
  • Vice Chairman,directors
  • 605.20K
  • Amarant Martínez Carrió
  • directors
  • --
  • David Ian Bell
  • directors
  • 222.00K
  • Tomás Dagá Gelabert
  • directors
  • 222.00K
  • jingyi pan
  • directors
  • --
  • yuewen zheng
  • directors
  • 239.60K
  • Bingyu Wang
  • Independent directors
  • 239.60K
  • ling peng
  • Independent directors
  • 239.60K
  • yamin chen
  • Independent directors
  • 239.60K
  • zheng liu
  • Board Secretary,Deputy General Manager
  • 4.35M
  • hong qiu
  • Securities affairs representative
  • --
  • weibing hu
  • Chairman of the Supervisory Board,Employee supervisors
  • 4.53M
  • Binh Hoang
  • auditors
  • 222.00K
  • yao li
  • auditors
  • 239.60K
  • zhengmin song
  • Deputy General Manager
  • 4.19M
  • jihui shen
  • Deputy General Manager
  • 4.19M
  • hui lu
  • Deputy General Manager
  • 4.20M
  • leqi chen
  • Head of finance
  • 3.66M
  • xuelian zhu
  • Head of Internal Audit
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
CN
Overall
Symbol
Latest Price
%Chg